Better Science, Better Health: New Trial Pathways and Better Patient Data
| INTRODUCTION | AGENDA | SPEAKERS | DOWNLOADS | PICTURES/VIDEOS |CONFERENCE REPORT |
PRESENTATIONS
New Pathways for Development and Better Patient Outcomes
- Stephen Whitehead, Chief Executive, ABPI
New Pathways & New Sources of Evidence. What do we need?
- Marc Trusheim, MIT Sloan School of Management
- Finn Børlum Kristensen, Executive Director, Eunetha
- Jillian Oderkirk, Senior Analyst, Health Division, OECD
High Quality Patient Data and MAPPs; Better Patient Outcomes, Faster and Cheaper
- Duane Schulthess, Managing Director, Vital Transformation
- Mohammad Al-Ubaydli, CEO, Patients Know Best
- Joel Haspel, Director Strategy & Business Development EMEA, Oracle Health Sciences
Blazing Trails – New Development Pathways in Action
- Sandrine Marreaud, Head of Medical and Pharmacovigilance Department, EORTC
- Ryan Hohman, Managing Director, Friends of Cancer Research
- Laura Esserman, Breast Cancer Center Director (I-Spy), University of California San Francisco
- James Anderson, Director of EU Industry & External Partnerships, GSK
- Edward Abrahams, President, Personalized Medicine Coalition (Moderator)
Real World Evidence – What works?
- Ifty Ahmed, CEO, Pow Health
- Jack Bowman, CEO, Handle My Health
- John Crawford, Healthcare Industry Leader, IBM Europe
- Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson (soon available)
- Geoff Wilson, HTA Task Force Leader, COCIR
The Patient’s Understanding of Benefit Risk
- Pat Furlong, CEO, Parent Project Muscular Dystrophy
- Sarah Garner, National Institutes of Clinical Excellence
- Andrea Beyer, Expert Benefit Risk Assessment
- Bettina Ryll, Founder, Melanoma Patient Network Europe
IMI2: Putting MAPPs Into Practice in Europe
- Jeremy Haigh, European Chief Operating Officer, Research & Development, Amgen Ltd.